{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:39:57Z","timestamp":1775543997448,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>56 patients with T2DM were randomised to antiplatelet monotherapy with aspirin 75\u00a0mg once daily (OD), clopidogrel 75\u00a0mg OD or prasugrel 10\u00a0mg OD during three periods of a crossover study. Platelet aggregation (PA) was determined by light-transmittance aggregometry and P-selectin expression by flow cytometry. Markers of fibrin clot dynamics, inflammation and coagulation were measured. Plasma levels of 14 miRNA were assessed by quantitative polymerase chain reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 56 patients, 24 (43%) were receiving aspirin for primary prevention of ischaemic events and 32 (57%) for secondary prevention. Prasugrel was the strongest inhibitor of ADP-induced PA (mean\u2009\u00b1\u2009SD maximum response to 20\u03bcmol\/L ADP 77.6\u2009\u00b1\u20098.4% [aspirin] vs. 57.7\u2009\u00b1\u200917.6% [clopidogrel] vs. 34.1\u2009\u00b1\u200914.1% [prasugrel], p\u2009&lt;\u20090.001), P-selectin expression (30 \u03bcmol\/L ADP; 45.1\u2009\u00b1\u200921.4% vs. 27.1\u2009\u00b1\u200919.0% vs. 14.1\u2009\u00b1\u200914.9%, p\u2009&lt;\u20090.001) and collagen-induced PA (2\u00a0\u03bcg\/mL; 62.1\u2009\u00b1\u200919.4% vs. 72.3\u2009\u00b1\u200918.2% vs. 60.2\u2009\u00b1\u200918.5%, p\u2009&lt;\u20090.001). Fibrin clot dynamics and levels of coagulation and inflammatory proteins were similar. Lower levels of miR-24 (p\u2009=\u20090.004), miR-191 (p\u2009=\u20090.019), miR-197 (p\u2009=\u20090.009) and miR-223 (p\u2009=\u20090.014) were demonstrated during prasugrel-therapy vs. aspirin. Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p\u2009=\u20090.039) or prasugrel (p\u2009=\u20090.0083).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prasugrel monotherapy in T2DM provided potent platelet inhibition and reduced levels of a number of platelet-associated miRNAs. miR-197 is a potential marker of cardiovascular disease in this population. Clinical outcome studies investigating prasugrel monotherapy are warranted in individuals with T2DM.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> EudraCT, 2009-011907-22. Registered 15 March 2010, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-011907-22\/GB\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-011907-22\/GB<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0981-3","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T11:06:26Z","timestamp":1578395186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A. E.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Temo","family":"Barwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fladia","family":"Phoenix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam M.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"9","key":"981_CR1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340\u20137.","journal-title":"Circ Res"},{"issue":"17","key":"981_CR2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation"},{"issue":"11","key":"981_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.2515","volume":"17","author":"SP Jackson","year":"2011","unstructured":"Jackson SP. Arterial thrombosis\u2013insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423\u201336.","journal-title":"Nat Med"},{"issue":"1","key":"981_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","volume":"16","author":"K Kearney","year":"2017","unstructured":"Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017;16(1):34.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"981_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.21037\/cdt.2018.05.09","volume":"8","author":"JR Rivas Rios","year":"2018","unstructured":"Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther. 2018;8(5):594\u2013609.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"10","key":"981_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/heartjnl-2015-307858","volume":"102","author":"WA Parker","year":"2016","unstructured":"Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart. 2016;102(10):783\u20139.","journal-title":"Heart"},{"issue":"7","key":"981_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"20","key":"981_CR8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"key":"981_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008;118:1626\u201336.","journal-title":"Circulation"},{"issue":"9038","key":"981_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329\u201339.","journal-title":"Lancet"},{"issue":"6","key":"981_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","volume":"90","author":"DL Bhatt","year":"2002","unstructured":"Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625\u20138.","journal-title":"Am J Cardiol"},{"key":"981_CR12","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:1840.","journal-title":"BMJ."},{"issue":"6","key":"981_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"M Pignone","year":"2010","unstructured":"Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the american diabetes association, a scientific statement of the american heart association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33(6):1395\u2013402.","journal-title":"Diabetes Care"},{"issue":"18","key":"981_CR14","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134\u201341.","journal-title":"JAMA."},{"issue":"23","key":"981_CR15","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60\u00a0years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510\u201320.","journal-title":"JAMA"},{"issue":"16","key":"981_CR16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"key":"981_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320\u20138.","journal-title":"Lancet"},{"key":"981_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","volume":"376","author":"JL Mega","year":"2010","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312\u20139.","journal-title":"Lancet"},{"issue":"5","key":"981_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1161\/ATVBAHA.109.183707","volume":"29","author":"RA Ajjan","year":"2009","unstructured":"Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009;29(5):712\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"981_CR20","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","volume":"35","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, Ecob R, Judge HM, Khan H, West LE, et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol. 2015;35(12):2562\u201370.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"981_CR21","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1160\/TH16-10-0799","volume":"117","author":"D Kiers","year":"2017","unstructured":"Kiers D, van der Heijden WA, van Ede L, Gerretsen J, de Mast Q, van der Ven AJ, El Messaoudi S, Rongen GA, Gomes M, Kox M, et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017;117(9):1798\u2013807.","journal-title":"Thromb Haemost"},{"issue":"3","key":"981_CR22","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","volume":"183","author":"T Morris","year":"2009","unstructured":"Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009;183(3):2089\u201396.","journal-title":"J Immunol."},{"issue":"2","key":"981_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/ATVBAHA.112.300141","volume":"33","author":"M Mayr","year":"2013","unstructured":"Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013;33(2):206\u201314.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"981_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1161\/CIRCRESAHA.111.300539","volume":"112","author":"P Willeit","year":"2013","unstructured":"Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, et al. Circulating MicroRNAs as novel biomarkers for platelet activation. Circ Res. 2013;112(4):595\u2013600.","journal-title":"Circ Res"},{"key":"981_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCRESAHA.114.305663","volume":"118","author":"D Kaudewitz","year":"2016","unstructured":"Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC, et al. Association of MicroRNAs and YRNAs with platelet function. Circ Res. 2016;118:420\u201332.","journal-title":"Circ Res"},{"issue":"4","key":"981_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jacc.2012.03.056","volume":"60","author":"A Zampetaki","year":"2012","unstructured":"Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard J-M, Mayr A, Weger S, Schett G, Shah A, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60(4):290\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"981_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"RF Storey","year":"2007","unstructured":"Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"981_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1055\/s-0037-1613242","volume":"88","author":"RF Storey","year":"2002","unstructured":"Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002;88:488\u201394.","journal-title":"Thromb Haemost"},{"key":"981_CR29","doi-asserted-by":"publisher","first-page":"e71150","DOI":"10.1371\/journal.pone.0071150","volume":"8","author":"S Neergaard-Petersen","year":"2013","unstructured":"Neergaard-Petersen S, Ajjan R, Hvas AM, Hess K, Larsen SB, Kristensen SD, Grove EL. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS ONE. 2013;8:e71150.","journal-title":"PLoS ONE"},{"key":"981_CR30","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","volume":"27","author":"A Carter","year":"2007","unstructured":"Carter A, Cymbalista C, Spector T, Grant P. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007;27:2783\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"981_CR31","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1160\/th15-06-0467","volume":"115","author":"F Franchi","year":"2016","unstructured":"Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni MM, Guzman LA, et al. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost. 2016;115(3):622\u201331.","journal-title":"Thromb Haemost."},{"issue":"8","key":"981_CR32","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","volume":"57","author":"K Hess","year":"2014","unstructured":"Hess K, Alzahrani SH, Price JF, Strachan MW, Oxley N, King R, Gamlen T, Schroeder V, Baxter PD, Ajjan RA. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. Diabetologia. 2014;57(8):1737\u201341.","journal-title":"Diabetologia"},{"issue":"6","key":"981_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1160\/th14-05-0468","volume":"112","author":"S Neergaard-Petersen","year":"2014","unstructured":"Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL, Larsen SB, Phoenix F, Kurdee Z, Grant PJ, Ajjan RA. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014;112(6):1142\u201350.","journal-title":"Thromb Haemost"},{"issue":"5","key":"981_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0003319706293132","volume":"57","author":"HS Al-Barjas","year":"2006","unstructured":"Al-Barjas HS, Ariens R, Grant P, Scott JA. Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm. Angiology. 2006;57(5):607\u201314.","journal-title":"Angiology"},{"issue":"4","key":"981_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"key":"981_CR36","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, et al. Platelet Inhibition with Ticagrelor 60\u00a0mg Compared with 90\u00a0mg Twice-daily in the PEGASUS-TIMI 54 study. J Am Coll Cardiol. 2016;67:1145\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"981_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hern\u00e1ndez-Antolin R, Moreno R, Escaned J, Alfonso F, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"981_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"981_CR39","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.110.226357","volume":"107","author":"A Zampetaki","year":"2010","unstructured":"Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al. Plasma microRNA profiling reveals loss of endothelial MiR-126 and other MicroRNAs in type 2 diabetes. Circ Res. 2010;107(6):810\u20137.","journal-title":"Circ Res"},{"issue":"1","key":"981_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-019-0875-4","volume":"18","author":"S Seidu","year":"2019","unstructured":"Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC, Khunti K. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):70.","journal-title":"Cardiovasc Diabetol."},{"issue":"Suppl 1","key":"981_CR41","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103\u201323.","journal-title":"Diabetes Care."},{"issue":"11","key":"981_CR42","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"},{"key":"981_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2017.11.013","volume":"161","author":"L Vernstrom","year":"2018","unstructured":"Vernstrom L, Funck KL, Grove EL, Laugesen E, Baier JM, Hvas AM, Poulsen PL. Antiplatelet effect of aspirin during 24\u00a0h in patients with type 2 diabetes without cardiovascular disease. Thromb Res. 2018;161:1\u20136.","journal-title":"Thromb Res"},{"issue":"6","key":"981_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3109\/09537104.2013.836175","volume":"25","author":"RR Joshi","year":"2014","unstructured":"Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. Platelets. 2014;25(6):416\u201322.","journal-title":"Platelets"},{"issue":"1","key":"981_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-019-0882-5","volume":"18","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Chen Q, Najera SD, Krishnan P, Lee ML, Cho DJ. Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. Cardiovasc Diabetol. 2019;18(1):77.","journal-title":"Cardiovasc Diabetol."},{"issue":"18","key":"981_CR46","doi-asserted-by":"publisher","first-page":"e012530","DOI":"10.1161\/JAHA.119.012530","volume":"8","author":"J Schmucker","year":"2019","unstructured":"Schmucker J, Fach A, Mata Marin LA, Retzlaff T, Osteresch R, Kollhorst B, Hambrecht R, Pohlabeln H, Wienbergen H. Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST-segment-elevation myocardial infarctions. J Am Heart Assoc. 2019;8(18):e012530.","journal-title":"J Am Heart Assoc."},{"issue":"5","key":"981_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1253\/circj.CJ-18-1113","volume":"83","author":"H Otsuki","year":"2019","unstructured":"Otsuki H, Yamaguchi J, Kawamoto T, Yoshikawa M, Ebihara S, Tanaka K, Nakao M, Jujo K, Arashi H, Ota Y, et al. Safety and efficacy of low-dose prasugrel as part of triple therapy with aspirin and oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention-from the TWMU-AF PCI registry. Circ J. 2019;83(5):1000\u20135.","journal-title":"Circ J"},{"issue":"17","key":"981_CR48","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1001\/jama.2012.17312","volume":"308","author":"PA Gurbel","year":"2012","unstructured":"Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785\u201394.","journal-title":"JAMA"},{"issue":"1","key":"981_CR49","doi-asserted-by":"publisher","first-page":"66.e69","DOI":"10.1016\/j.ahj.2006.10.010","volume":"153","author":"JT Brandt","year":"2007","unstructured":"Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e69.","journal-title":"Am Heart J"},{"issue":"2","key":"981_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1538-7836.2009.03700.x","volume":"8","author":"AA Kondkar","year":"2010","unstructured":"Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, et al. VAMP8\/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010;8(2):369\u201378.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"981_CR51","doi-asserted-by":"publisher","first-page":"e0145930","DOI":"10.1371\/journal.pone.0145930","volume":"10","author":"C Schulte","year":"2015","unstructured":"Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, Hartmann T, Lackner KJ, Westermann D, Schnabel RB, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS ONE. 2015;10(12):e0145930.","journal-title":"PLoS ONE"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0981-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:17:48Z","timestamp":1609892268000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0981-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0981-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"10 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by NHS Research Ethics Service (reference 09\/H1307\/110). Written consent was obtained from participants before any study activities took place.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M Mayr filed and licensed patent applications on miRNAs as biomarkers (EP15193448.6, EP2776580 B1, DE112013006129T5, GB2524692A, EP2576826 B, JP2013-513740). M. Mayr filed and licensed patent applications on miRNAs as biomarkers (EP15193448.6, EP2776580 B1, DE112013006129T5, GB2524692A, EP2576826 B, JP2013-513740).RF Storey reports institutional research grants\/support from AstraZeneca and GlyCardial Diagnostics; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, GlyCardial Diagnostics, Haemonetics, Idorsia, Novartis, Portola and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer and Medscape. R. Ajjan. received honoraria and educational and research support from Abbott Diabetes Care, AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, Sanofi, MSD, and Boehringer Ingelheim. The other authors report no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}